Fujifilm India targets revenue growth by 35 %, a health care imprint by 2030

Fujifilm India is preparing for the next stage of expansion in the field of health care, with the aim of maintaining two numbers by 2029 with new facilities, wider service coverage and stronger partnerships throughout the country.

“The company aims to increase by 35 % in the total revenues and margins operating by more than 15 % by 2030,” said Koji Wada, Managing Director of Fujifilm India. The profits will be reinforced into growth initiatives to create what he described as a “permanent growth cycle”.

“Our health care works have grown steadily over the past three years to the past five, and we expect this path to continue. Cow and MRI systems (CT) remain important drivers, especially in triple hospitals and diagnostic centers, while theorizing has gained wider acceptance in the past four years by creating the product and supporting service.”

According to CMIE data, the revenue of the medical sector in Fujifilm India increased by 16 % on an annual basis to approximately 11,168.49 rupees in fiscal year 24, up from 9,634.16 crushers in the previous year. Its non -medical works grew more than 18 % on an annual basis, reaching 6,093.89 rupees in the same period.

The company plans to expand its network from the health organization of Amnesty International to 100 sites by FY2030 solutions, based on its base, which includes more than 73,000 imaging systems installed at the country level, including a strong presence in non -metro cities.

The service and training remain essential for its expansion strategy. “We were able to build the range in the cities of level 2 and Tier 3 due to the country’s support network, which ensures the availability of equipment, time maintenance and training of users. These factors are necessary for adoption in areas where the diagnostic infrastructure is still developing,” explained Wada.

To support this growth, Fujifilm India adds a new infrastructure – including a new endoscopy this year and a new headquarters for companies in Gurgaon’s DLF CyberCity, which will serve as a office space and a medical call center.

When manufacturing, Wada said that “Make in India” is part of the long -term agenda, where the departments evaluate the requirements of a possible local base. He added: “We give priority to developing human capital before increasing investment.”

Partnerships remain at the heart of India’s strategy in India. Fujifilm Dkh LLP runs the preventive health care arm in Nora, and in December 2024, the company opened the Nura Global Development Center in Kozhikode, Kerala State. The company is also cooperating with Indian technology companies to bring its capabilities to health care solutions.

On the global level, Fujifilm varied in pharmacy and life sciences, and WADA confirmed that India is evaluating opportunities in these areas. He said: “Medicines and life science has produced good results at the international level, especially in the United States. In India, we also explore options to participate in these sectors.”

Wada concluded that “our ambition in India is to support comprehensive health care through products, solutions and technology. This directs the next stage of our work here.”